Loading organizations...
§ Private Profile · 55 Cambridge Parkway Suite 800E Cambridge, MASSACHUSETTS UNITED STATES
Biotechnology company developing a novel cell therapy platform for diverse diseases, focused on new therapeutic functions.
Key people at Flagship Labs 68 Inc.
Flagship Labs 68 Inc was founded in 2019 by Brad Kubick (Co-founder and Head of Innovation).
Flagship Labs 68 Inc is a Cambridge, Massachusetts-based early-stage biotechnology company developing a novel cell therapy platform that leverages unique cell behaviors for new therapeutic functions. The enterprise currently focuses on characterizing previously overlooked cellular mechanisms to build a multi-modality platform targeting cures across a diverse spectrum of human diseases. Operating as a privately held entity, the startup is fully resourced by its parent venture creation engine, Flagship Pioneering, which manages over $3 billion in capital commitments and directly employs 475 professionals. This parent organization has historically generated an aggregate portfolio value exceeding $30 billion through the creation of over 100 ventures, including notable biotechnology firms such as Moderna, Rubius Therapeutics, and Editas Medicines. Flagship Labs 68 Inc was officially founded in 2020 by Flagship Pioneering and its founder and chief executive officer, Noubar Afeyan.
Key people at Flagship Labs 68 Inc.
Flagship Labs 68 Inc was founded in 2019 by Brad Kubick (Co-founder and Head of Innovation).
Flagship Labs 68 Inc. (FL68) is a privately held, well-funded early-stage biotechnology company founded by Flagship Pioneering, focused on developing novel cell therapies to revolutionize cell therapeutics.[1][2] It targets advancements in cellular immunology, stem cell biology, and bioprocessing, serving the biotech sector by addressing challenges in cell-based treatments for diseases.[1][2][5] The company operates from Cambridge, MA, with active hiring in specialized scientific roles, indicating growth momentum in its preclinical pipeline.[3][5]
Flagship Labs 68 Inc. emerged from Flagship Pioneering, a venture creation firm with over 25 years of experience inventing and building platform companies in life sciences, including Moderna and Generate:Biomedicines.[1][4] Founded as an early-stage biotech spinout, FL68 leverages Flagship's expertise in pioneering transformative therapies, with no specific public details on individual founders but rooted in the firm's network of scientists and entrepreneurs.[1][2][4] Early traction is evident from its well-funded status and job postings for roles like Scientist in Cellular Immunology and Senior Research Associate in Bioprocessing, signaling rapid team-building post-founding.[1][2]
FL68 rides the explosive growth in cell and gene therapies, a market projected to expand amid advances in immunotherapy and regenerative medicine, fueled by successes like CAR-T treatments and Flagship's own Moderna (mRNA vaccines).[1][4] Timing is ideal post-2020s biotech boom, with market forces like aging populations, autoimmune disease prevalence, and partnerships (e.g., Flagship's deals with Pfizer, GSK, Genentech) creating tailwinds for cell therapy innovators.[4] It influences the ecosystem by contributing to Flagship's constellation of 20+ companies, accelerating platform technologies that de-risk downstream ventures and attract big pharma collaborations.[4]
FL68 is poised for milestones like preclinical data readouts or Series A funding in 2026, as it scales its cell therapy platform amid surging demand for next-gen immunotherapies.[1][2] Trends like AI-driven drug design (seen in Flagship peers like Generate) and regulatory streamlining for cell therapies will shape its path, potentially leading to IND filings or acquisitions.[4] Its influence may grow by exemplifying Flagship's model—turning bold science into ecosystem-defining companies—primed to revolutionize cell therapeutics as promised.[1]
